Development of small molecule inhibitors of the Pseudomonas aeruginosa biofilms to treat chronic infections in cystic fibrosis patients (360G-Wellcome-106310_Z_14_B)
Cystic fibrosis is the most common lethal, hereditary disease in Caucasian populations, affecting 1 in every 3,500 births in Europe with a current life expectancy of about 38 years. Most disease-related morbidity and mortality in CF is caused by progressive lung disease as a result of bacterial infection and airway inflammation, primarily associated with the effects of chronic Pseudomonas aeruginosa (PA) lung infection and the persistence of PA biofilms. The Trust has awarded Antabio €4.0m over 2 years to fund the development of a small molecule inhibitor of PA biofilms to be used in combination with standard-of-care antibiotics. The objective of the project team, led by Principal Investigator Dr Martin Everett, Head of Biology at Antabio, is to identify a potent and selective lead series with efficacy in animals which will be capable of further development into a drug to augment the effectiveness of antibiotic therapy and result in enhanced suppression of the infection.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 116882 |
Applicant Surname | Everett |
Approval Committee | Seeding Drug Discovery Committee |
Award Date | 2017-10-01T00:00:00+00:00 |
Financial Year | 2017/18 |
Grant Programme: Title | Seeding Drug Discovery Award |
Internal ID | 106310/Z/14/B |
Lead Applicant | Dr Martin Everett |
Partnership Value | 116882 |
Planned Dates: End Date | 2017-05-31T00:00:00+00:00 |
Planned Dates: Start Date | 2017-05-01T00:00:00+00:00 |
Recipient Org: Country | France |
Region | International |